BLZ-945

CHF 192.00
In stock
SYN-1197-M0011 mgCHF 192.00
SYN-1197-M0055 mgCHF 419.00
SYN-1197-M01010 mgCHF 658.00
SYN-1197-M05050 mgCHF 2'214.00
SYN-1197-M100100 mgCHF 3'531.00
 
More Information
Product Details
Synonyms BLZ945
Product Type Chemical
Properties
Formula C20H22N4O3S
MW 398.5
CAS 953769-46-5
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: c-FMS | Kinase Group: PTK | Substrate: Tyrosine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key ADZBMFGQQWPHMJ-RHSMWYFYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
BLZ945 is an orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R) inhibitor, which inhibits CSF-1R activity with an IC(50) of 1nM and is more than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and Platelet-derived Growth Factor Receptor β (PDGFRβ ) as well as more than 200 additional kinases, confirming the selectivity of the compound.
Product References
  1. Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics: T. Wang, et al.; Int. J. Toxicol. 30, 300 (2011)
  2. CSF-1R inhibition alters macrophage polarization and blocks glioma progression: S.M. Pyonteck, et al.; Nat. Med. 19, 1264 (2013)
  3. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells: D.C. Strachan, et al.; Oncoimmunology 2, e26968 (2013)
  4. Therapeutically reeducating macrophages to treat GBM: C. Garris & M.J. Pittet; Nat. Med. 19, 1207 (2013)
  5. Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite: J.A. Krauser, et al.; Xenobiotica 45, 107 (2015)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.